Demonacos C - Search Results

1

Insight into glucocorticoid receptor signalling through interactome model analysis.

Bakker E, Tian K, Mutti L, Demonacos C, Schwartz JM, Krstic-Demonacos M. Bakker E, et al. Among authors: demonacos c. PLoS Comput Biol. 2017 Nov 6;13(11):e1005825. doi: 10.1371/journal.pcbi.1005825. eCollection 2017 Nov. PLoS Comput Biol. 2017. PMID: 29107989 Free PMC article.

2

Quantitative analysis and modeling of glucocorticoid-controlled gene expression.

Chen DW, Lynch JT, Demonacos C, Krstic-Demonacos M, Schwartz JM. Chen DW, et al. Among authors: demonacos c. Pharmacogenomics. 2010 Nov;11(11):1545-60. doi: 10.2217/pgs.10.125. Pharmacogenomics. 2010. PMID: 21121775

3

Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.

Qattan MY, Bakker EY, Rajendran R, Chen DW, Saha V, Liu J, Zeef L, Schwartz JM, Mutti L, Demonacos C, Krstic-Demonacos M. Qattan MY, et al. Among authors: demonacos c. PLoS One. 2017 Jun 5;12(6):e0178606. doi: 10.1371/journal.pone.0178606. eCollection 2017. PLoS One. 2017. PMID: 28582465 Free PMC article.

4

The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression.

Lynch JT, Rajendran R, Xenaki G, Berrou I, Demonacos C, Krstic-Demonacos M. Lynch JT, et al. Among authors: demonacos c. Mol Cancer. 2010 Feb 15;9:38. doi: 10.1186/1476-4598-9-38. Mol Cancer. 2010. PMID: 20156337 Free PMC article.

5

Regulation of glucocorticoid receptor activity by a stress responsive transcriptional cofactor.

Davies L, Paraskevopoulou E, Sadeq M, Symeou C, Pantelidou C, Demonacos C, Krstic-Demonacos M. Davies L, et al. Among authors: demonacos c. Mol Endocrinol. 2011 Jan;25(1):58-71. doi: 10.1210/me.2010-0212. Epub 2010 Dec 8. Mol Endocrinol. 2011. PMID: 21147850 Free PMC article.

6

The role of microenvironment and immunity in drug response in leukemia.

Bakker E, Qattan M, Mutti L, Demonacos C, Krstic-Demonacos M. Bakker E, et al. Among authors: demonacos c. Biochim Biophys Acta. 2016 Mar;1863(3):414-426. doi: 10.1016/j.bbamcr.2015.08.003. Epub 2015 Aug 6. Biochim Biophys Acta. 2016. PMID: 26255027 Free article. Review.

7

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.

Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L. Guazzelli A, et al. Among authors: demonacos c. Expert Opin Investig Drugs. 2017 Aug;26(8):933-944. doi: 10.1080/13543784.2017.1351545. Epub 2017 Jul 12. Expert Opin Investig Drugs. 2017. PMID: 28679291 Free article. Review.

8

Immunotherapy advances for mesothelioma treatment.

Bakker E, Guazzelli A, Ashtiani F, Demonacos C, Krstic-Demonacos M, Mutti L. Bakker E, et al. Among authors: demonacos c. Expert Rev Anticancer Ther. 2017 Sep;17(9):799-814. doi: 10.1080/14737140.2017.1358091. Epub 2017 Jul 31. Expert Rev Anticancer Ther. 2017. PMID: 28724330 Free article. Review.

9

p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.

Tian K, Bakker E, Hussain M, Guazzelli A, Alhebshi H, Meysami P, Demonacos C, Schwartz JM, Mutti L, Krstic-Demonacos M. Tian K, et al. Among authors: demonacos c. J Transl Med. 2018 Oct 13;16(1):282. doi: 10.1186/s12967-018-1650-0. J Transl Med. 2018. PMID: 30316293 Free PMC article.

10

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment.

Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M, Mutti L. Guazzelli A, et al. Among authors: demonacos c. Int J Mol Sci. 2019 Jan 19;20(2):429. doi: 10.3390/ijms20020429. Int J Mol Sci. 2019. PMID: 30669483 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page